GlobeNewsWire
28 May 2026, 05:15 UTC · 2h ago
Source · https://www.globenewswire.com/news-release/2026/05/28/3302503/0/en/Basilea-receives-further-USD-13-million-from-BARDA-to-continue-development-of-novel-antibiotic-ceftibuten-ledaborbactam.html
Read source
Search tags
Story key points
3 claims · impact-rated
Basilea's contract with BARDA could provide up to USD 133 million in additional non-dilutive funding. — Significant non-dilutive capital reduces the need for equity raises and improves the company's cash runway.
+0.60Basilea received a further USD 13.3 million from BARDA to advance the development of ceftibuten-ledaborbactam, bringing total committed funding to USD 25 million. — Immediate funding validates the asset's potential and provides capital for clinical development.
+0.40The funding will be used to prepare the clinical phase 3 program for the treatment of complicated urinary tract infections (cUTIs). — Moving toward Phase 3 is a critical regulatory milestone that increases the probability of eventual commercialization.
+0.30Ticker attribution
Model heads
The company received non-dilutive funding from BARDA to advance a novel antibiotic candidate toward phase 3 trials.
No ticker relationship head found.
Impact vectors
4 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
